Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Agenus announced early Phase 2 results for the dMMR colon cancer cohort of NEOASIS, an investigator-initiated study sponsored by the Netherlands Cancer Institute. The excerpt identifies the tested combination as botensilimab plus balstilimab, administered before surgery, but does not provide the results or their direction.

Analysis

The supplied text does not include the actual efficacy or safety results, so it is not possible to judge whether this is clinically or commercially positive. The key potential value driver is whether adding BOT to BAL produces a meaningful advantage over PD-1 monotherapy in dMMR disease—a setting already sensitive to checkpoint inhibition. Without a credible incremental benefit, a two-drug regimen could add toxicity and perioperative complexity without expanding the treatable population.

The presurgical setting creates a near-term read-through opportunity but also raises a distinct risk: immune-related toxicity or treatment-related delay could interfere with surgery. An investigator-initiated study sponsored by NKI offers external academic involvement, but it does not by itself establish reproducibility, commercial adoption, or Agenus’ ability to scale the regimen. Any share reaction to a headline should be discounted until cohort size, pathological response, safety, surgery timing, follow-up, and comparator context are clear.

Over 1–3 months, the catalyst is fuller data and evidence of follow-up or a defined next trial; over 6–18 months, the question is whether results replicate and support a treatment-changing role. Established checkpoint options, including pembrolizumab and dostarlimab, are relevant benchmarks. No fundamental trade signal is supported by the text provided.

Key Decisions for Investors

• Do not trade the headline alone: the supplied article omits the underlying results. Treat AGEN as a clinical-event watch pending the full presentation or release.
• Before considering a speculative long, verify cohort size, pathological complete/major response rates, duration of follow-up, grade and type of immune-related adverse events, and whether treatment delayed or prevented surgery. Compare outcomes with relevant PD-1-based benchmarks.
• If fuller data show a clear efficacy increment without material perioperative or immune-toxicity costs, reassess AGEN for a catalyst-driven position; size for binary clinical risk rather than assuming broad adoption.
• Falsification / thesis risk: weak or immature response data, meaningful surgery delays, serious toxicity, or no credible path to replication would undermine the differentiation case. Monitor subsequent trial design and enrollment rather than extrapolating this cohort to all dMMR cancers.